摘要:
The invention concerns new amino acid derivatives of general formula (I): R?1-R11-A1¿-B, and pharmaceutically acceptable salts thereof, wherein the group B represents -A?2- NR2R3 or R5, R1, A1, A2, R2, R3, R5 and R11¿ having the meanings indicated in the description. The invention also concerns the production and use of these compounds. The new compounds are valuable neurokinine (tachykinine) antagonists.
摘要:
The invention concerns novel amino acid derivatives of general formula (I) and their pharmaceutically acceptable salts, in which the R2 group is (II) and R1, A, G, Y, Z and m have the meanings given in the description, and their production and use. The novel compounds are valuable neurokinin (tachykinin) antagonists.
摘要:
The invention relates to novel pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, joint, skin or eye inflammatory diseases, disease of the periphery or central nervous system or cancer. The invention also relates to pharmaceutical compositions containing said compounds.
摘要:
The invention relates to novel pteridines which can be used in the treatment of respiratory or gastrointestinal complaints or diseases, joint, skin or eye inflammatory diseases, diseases of the periphery or central nervous system or cancer. The invention also relates to pharmaceutical compositions which contain said compounds.
摘要:
Object of the present invention are novel substituted compounds of the formula 1, wherein A, R 1 , R 2 , R 3 and R 4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
摘要:
The invention relates to the novel piperidino-dihydrothienopyrimidines of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO2, preferably however SO, and wherein R1, R2, R3 and R4 are defined as in claim 1. The invention also relates to pharmaceutical compositions containing said compounds. The novel piperidino-dihydrothienopyrimidines are suitable for use in the treatment of respiratory or gastrointestinal disorders or diseases, inflammatory diseases of the joints, the skin or the eyes, diseases of the peripheral or central nervous system or cancers.
摘要:
The invention relates to the novel dihydrothienopyrimidine sulfoxides of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO2, preferably however SO, and wherein R3 represents an optionally substituted, monocyclic or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, monocyclic or bicyclic heteroaryl, and wherein R1 and R2 are defined as in claim 1. The invention also relates to pharmaceutical compositions containing said compounds. The novel dihydrothienopyrimidine sulfoxides are suitable for use in the treatment of respiratory or gastrointestinal disorders or diseases, inflammatory diseases of the joints, the skin or the eyes, diseases of the peripheral or central nervous system or cancers.
摘要:
The invention relates to the use of pteridines for the treatment of inflammatory and obstructive diseases of the respiratory tract, preferably asthma or COPD, and pharmaceutical compounds containing said compounds.
摘要:
Use of a compound of general formula 1 for manufacturing a medicament to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, in particular compounds of formula 1: wherein R , R , R , A, B, X, W, Z, i, j, k, l and m are defined as in the description and claims. It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
摘要:
The invention concerns novel amino acid derivatives of general formula (I) and their pharmaceutically acceptable salts, in which the R2 group is (II) and R1, A, G, Y, Z and m have the meanings given in the description, and their production and use. The novel compounds are valuable neurokinin (tachykinin) antagonists.